Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age. PCOS is not only the leading cause of anovulatory infertility but is also associated with an array of metabolic disorders, among which impaired glucose metabolism has been a topic of intense research. The aim of the present narrative review is to summarize the findings of the studies that have evaluated the prevalence and incidence of prediabetes and type 2 diabetes mellitus (T2DM) in patients with PCOS, to analyze the factors underpinning the association between T2DM and PCOS and to discuss the current strategies for screening and management of impaired glucose metabolism in this population. Both prediabetes and T2DM are highly prevalent in patients with PCOS. Accordingly, regular screening is recommended in this population for the early identification of impaired glucose metabolism, particularly in overweight or obese patients and in those with a family history of T2DM. Prevention of T2DM in patients with prediabetes is primarily based on lifestyle changes, while metformin might be considered in selected cases. The treatment of T2DM is similar in patients with and without PCOS but appropriate contraceptive measures should be implemented in patients receiving treatments other than insulin, metformin or glyburide.
INTRODUCTION
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive 1,2 PCOS is mainly characterized by oligo-or anovulation, clinical and/or biochemical hyperandrogenism and polycystic ovaries and is the leading cause 3, 4 However, PCOS is also associated with an array of metabolic disorders, among which impaired glucose metabolism has been a topic and some prospective studies reported increased prevalence and incidence of impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM) in 5 The aim of the present narrative review is to summarize the findings of the studies that evaluated the prevalence and incidence of prediabetes and T2DM in patients with PCOS, to discuss the factors underpinning the association between T2DM and PCOS and to present the current recommendations for screening for and management of impaired glucose metabolism in of a systematic review or a meta-analysis because the heterogeneity of the studies included in the review is too large, rendering the systematic review and the
METHODS
We searched the PubMed for relevant articles using the following keywords: polycystic ovary syndrome, impaired fasting glucose, impaired glucose tolerance, type 2 diabetes mellitus, prediabetes, insulin resistretrieved articles were also evaluated for the identi-
PREVALENCE OF PREDIABETES AND T2DM IN PATIENTS WITH PCOS
In an early case-control study in 254 patients with PCOS and 80 age-and weight-matched controls, the 6 patients with PCOS had T2DM compared with none 6 In a more recent large study in 11,035 patients with PCOS, the preva- 7 In a meta-analysis of 13 studies that compared the prevalence of IGT between patients 5 Likewise, the prevalence of than in controls in a meta-analysis of 15 studies 5 and, importantly, these differences were similar in studies that included body mass index (BMI)-matched popula-5 of all incident cases of T2DM in white women are 8 Metabolic syndrome, which is associated with increased risk for T2DM, 9 is also more frequent in patients with PCOS, 10,11 while, in contrast, the prevalence of impaired fasting glucose or of HbA1c -12,13
INCIDENCE OF PREDIABETES AND T2DM IN PATIENTS WITH PCOS
There are very limited data on the incidence of early uncontrolled study in 67 patients with PCOS, developed IGT and T2DM, respectively, during a 14
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In a more recent study in 95 patients with PCOS and age-and BMI-matched controls, the incidence of T2DM during an 8-year follow-up period was 15 Moreover, obese patients with PCOS had a fivefold greater risk of developing T2DM than 15 In another study, the incidence of IGT was albeit this difference did not reach significance due to 16 In a more recent uncontrolled study in 255 patients age-standardized prevalence of T2DM at the end of follow-up was significantly higher than that of the 17 In another recent retrospective analysis of a large longitudinal database, patients with PCOS (n = 21,740) had a 3 times higher risk of 18 times higher in patients with PCOS than in BMI-
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PATHOGENESIS OF PREDIABETES AND T2DM IN PCOS
Insulin resistance (IR) is intimately involved in the increased risk for prediabetes and T2DM in PCOS, 14 19, 20 In addition, IR worsens with 21, 22 The pathogenesis of 23 Insulinstimulated glucose uptake is mediated by the activation of phosphatidylinositol-3 kinase, while insulin-induced cell growth and differentiation is mediated through the mitogen-activated protein kinase (MAPK) http:// and-molecular-biology/mapk-erk-pathway/ extracellular signal-regulated kinase (ERK) that stimulates a cascade of enzymes, including serine/threonine, 24 A pivotal study in obese and non-obese patients with PCOS showed that IR in this syndrome is independent of obesity and is 23 More recent studies also support the presence of an intrinsic IR in patients 25, 26 Higher basal insulin secretory rates and attenuated secretory responses to meals have also been reported in patients with PCOS, which factors [27] [28] [29] In contrast, insulin clearance does not appear to be 23 PCOS and is another key contributor to the pathogenesis of impaired glucose metabolism in this popula- 11, 30, 31 In a case-control study in 254 patients with PCOS and 80 age-and weight-matched controls, both BMI and waist/hip ratio (WHR) were independent predictors of IGT, 6 while other studies have also reported higher BMI and WHR in patients with PCOS and IGT than in those with normal glucose 32, 33 In prospective studies, obesity was also independently associated with increased incidence 14 Obesity appears to exert a synergistic, independent, adverse effect on glucose metabolism, this accompanied by the added burden of intrinsic IR that characterizes 23 Body composition, including increased ratio of truncal/lower body fat and higher inter-and intramuscular adipose tissue also contribute 34, 35 Hyperandrogenism might also play a role in the Indeed, patients with PCOS and hyperandrogenemia have more pronounced IR than patients without hy- [36] [37] [38] It has further been shown that treatment with androgens impairs insulin sensitivity, whereas antiandrogens improve insulin sensitivity, [39] [40] [41] while in addition it appears that IR aggravates obesity 42, 43 Moreover, several studies reported that free testosterone levels are higher in patients with PCOS and IGT than in those with 33 Impaired glucose metabolism in patients with PCOS additionally appears to have a strong genetic background, since a positive family history of T2DM increases the risk for IR and prediabetes in this popu- 44 Moreover, women with monozygotic twin sisters with PCOS have twice the risk of developing 45 In a number of studies, polymorphisms in several genes, including thyroid associated protein, DENN/MADD domain containing 1A and luteinising hormone/choriogonadotropin receptor, were associ- [44] [45] [46] [47] [48] Developmental the presence of increased steroids, mostly androgens, during fetal development, also appears to increase the risk for IR, prediabetes and T2DM in offspring 49 Emerging data suggest that the gut microbiome might also be implicated in the pathogenesis of im-
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In a recent pilot study, specific taxa of gut bacteria were associated with lower serum androgen levels 51 Muscle mitochondrial dysfunction has also been recently reported in patients with PCOS and might also play a role in the development of T2DM in this 52 
SCREENING FOR PREDIABETES AND T2DM IN PATIENTS WITH PCOS
MANAGEMENT OF PREDIABETES AND T2DM IN PATIENTS WITH PCOS
Lifestyle changes, including diet, exercise and behavior modification, represent first-line treatment 53, 56, 57 A hypocaloric diet (500-1000 kcal/d reduction) with reduced intake of saturated fats and increased intake of mono-and polyunsaturated fats, fiber, whole-grain breads, cereals, fruits and vegetables is recommended, along with at least 30 min of moderate-intensity physi-56,57 A reduced carbohydrate diet also appears to result in preferential loss of abdominal 58 It is well established that diet improves IR in patients with PCOS, [59] [60] [61] while exercise also appears to improve IR and to reduce visceral fat in 62, 63 Lifestyle changes reduced the risk of progression from IGT to T2DM in the general population 64,65 66 Additionally, the Androgen Excess and PCOS Society as well as the Endocrine Society suggest the use of metformin in patients with PCOS who have no improvement in IGT despite lifestyle changes and in 56, 57 Several studies showed that treatment with metformin improves IR and induces weight loss in patients with PCOS and that it might also induce reversion from IGT to normal glucose tolerance and prevent the development of IGT [67] [68] [69] [70] However, it should be noted that in the Diabetes Prevention Program study (n = 3,234 patients with IFG or IGT), metformin was less effective than lifestyle changes in reducing the incidence of T2DM 62 Importantly, the use of antiobesity agents is not recommended because of limited data on their safety and efficacy 57, 61, 71 In patients with PCOS who are diagnosed with T2DM there are no specific recommendations for 72 Accordingly, metformin and lifestyle changes are the treatment of choice, while any antidiabetic agent can be added in patients who do not achieve glycemic targets despite -itazone, dipeptidyl peptidase 4 inhibitors, glucagonlike peptide-1 receptor agonists, sodium-glucose 72 Among the available options, pioglitazone appears to improve insulin sensitivity to a similar degree as metformin, both agents exerting a synergistic effect on IR in 73, 77 However, safety concerns, including the risk of weight gain and edema, limit 54 Limited data also suggest that glucagon-like peptide 1 analogues combined with metformin attenuate IR and reduce weight more effectively than metformin 75, 76 However, only insulin, metformin and glyburide can be safely used in pregnancy and therefore appropriate contraceptive measures should be implemented in patients receiving other antidia-
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CONCLUSIONS
Both prediabetes and T2DM are highly prevalent -ing is recommended in this population for the early identification of impaired glucose metabolism, particularly in overweight or obese patients and in those in patients with IGT is primarily based on lifestyle changes, whereas metformin might be considered in beneficial effects on glucose metabolism in this popuwith and without PCOS but appropriate contraceptive measures should be implemented in patients receiving 
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